Education
About Us
Working with TipRanks
Follow Us
Longeveron (LGVN)
NASDAQ:LGVN
LGVN Stock Chart & Stats
$0.62
-$0.07(-3.68%)
At close: 4:00 PM EST
$0.62
-$0.07(-3.68%)
Day’s Range― - ―
52-Week Range$0.49 - $1.92
Previous CloseN/A
Volume215.49K
Average Volume (3M)473.11K
Market Cap
$12.51M
Enterprise Value$10.32M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$983.00K
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding19,848,877
10 Day Avg. Volume706,553
30 Day Avg. Volume473,105
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.18
Price to Sales (P/S)10.77
P/FCF Ratio-1.73
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue7.18
Enterprise Value/Gross Profit9.59
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$3.50Price Target Upside464.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressSurvival data has been encouraging from ELPIS I long-term follow-ups, with 100% survival at 5 years of age compared to a 20% mortality at 5 years for historical control.
Financial SupportGrant funding from the National Institute of Health helps offset study expenses, enhancing the company's financial position.
Regulatory EnvironmentThe first approved mesenchymal cell therapy continues to gain traction in another pediatric rare disease at premium pricing and an overall more favorable regulatory environment for cell-based therapies.
Bears Say
Equity FinancingThe company's recent equity financing has led to dilution, which has contributed to a lowered 12-month price target from $6.00 to $4.00.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.49 and its highest was $1.92 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $12.51M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Mar 06, 2026 which is in 56 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on Nov 04, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.255 by -$0.135.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -0.37.
How many shares outstanding does Longeveron have?
Longeveron has 19,848,877 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.255. Following the earnings report the stock price went down -4.75%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
LGVN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture for Longeveron. While there were significant advancements in clinical trials and a robust pipeline with favorable FDA designations, the company also faces financial challenges, including declining revenues, increased expenses, and potential delays in regulatory filings. Longeveron is actively seeking partnerships and additional funding to address these challenges.View all LGVN earnings summariesLGVN Stock 12 Month Forecast
Average Price Target
$3.50
▲(464.52% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
13.86% Insiders
2.92% Mutual Funds
0.44% Other Institutional Investors
80.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---